Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Reaffirmed as Outperform by Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $165.00 price objective on the stock. Wedbush‘s price objective would suggest a potential upside of 79.45% from the stock’s previous close.

Several other equities research analysts have also issued reports on the company. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research report on Tuesday. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 3rd. Finally, UBS Group increased their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $133.00.

Oruka Therapeutics Stock Up 1.8%

Shares of NASDAQ:ORKA opened at $91.95 on Tuesday. Oruka Therapeutics has a twelve month low of $25.23 and a twelve month high of $115.51. The stock’s 50 day moving average is $89.99 and its 200-day moving average is $67.22. The firm has a market capitalization of $6.09 billion, a price-to-earnings ratio of -45.39 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $83.62, for a total transaction of $2,090,500.00. Following the completion of the sale, the chief executive officer owned 923,128 shares in the company, valued at approximately $77,191,963.36. This trade represents a 2.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $80.60, for a total value of $805,919.40. Following the sale, the senior vice president owned 14,219 shares of the company’s stock, valued at approximately $1,146,051.40. This trade represents a 41.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 154,950 shares of company stock worth $14,102,680. 23.49% of the stock is currently owned by insiders.

Institutional Trading of Oruka Therapeutics

Large investors have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at about $2,874,000. Sei Investments Co. boosted its position in shares of Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock valued at $1,120,000 after acquiring an additional 13,164 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Oruka Therapeutics by 517.1% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,310 shares of the company’s stock valued at $9,927,000 after buying an additional 87,408 shares in the last quarter. Handelsbanken Fonder AB purchased a new position in shares of Oruka Therapeutics during the 2nd quarter valued at about $15,313,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Oruka Therapeutics during the 1st quarter valued at about $5,543,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Strong psoriasis efficacy data: In the ongoing EVERLAST-B Phase 2b trial, 61% of patients receiving the 600 mg dose achieved complete skin clearance (PASI 100) at Week 16, while 86% achieved at least 90% clearance (PASI 90). Oruka said the results were consistent with the earlier EVERLAST-A trial and that the drug maintained a favorable safety and tolerability profile. Oruka Announces Positive Week 16 Results
• Positive Sentiment: Path toward pivotal development: Management expects ORKA-001 to advance into Phase 3 trials in the first half of 2027. Additional catalysts include 52-week EVERLAST-A data expected in December 2026 and ORKA-002 Phase 2 psoriasis results anticipated in the first quarter of 2027. Positive Week 16 Results for ORKA-001
• Positive Sentiment: Analyst support increased: Wedbush reaffirmed its “outperform” rating and raised or maintained a $165 price target, implying substantial upside from recent trading levels. Guggenheim also suggested ORKA-001 could generate as much as $7 billion in peak sales if successfully developed and commercialized. Wedbush Stock Recommendations
• Neutral Sentiment: Short-interest data showed no reported short position: The latest report listed short interest at zero shares and a zero-day days-to-cover ratio. This may reduce evidence of bearish positioning, although the figure could reflect a reporting or data anomaly rather than a meaningful change in investor sentiment.
• Negative Sentiment: Insider selling remains a concern: Recent trading data showed no insider purchases and numerous insider sales, including sales by executives and a large fund position. Such activity can weigh on sentiment even as the clinical outlook improves.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.